InnoCan Pharma Corporation (CSE:INNO)

InnoCan Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	26.61	29.44	13.66	2.56	0.2
Revenue Growth (YoY)	-9.60%	115.55%	433.69%	1205.61%	2350.00%
Cost of Revenue	2.68	3.25	1.68	0.45	0.08
Gross Profit	23.93	26.19	11.98	2.11	0.12
Selling, General & Admin	24.25	25.89	13.99	6.85	6.2
Research & Development	0.93	1.55	1.8	1.53	1.4
Operating Expenses	25.19	27.43	15.78	8.37	7.6
Operating Income	-1.26	-1.25	-3.8	-6.27	-7.48
Interest Expense	-0	-0.01	-	-0	-0.01
Currency Exchange Gain (Loss)	0.03	-0.04	0	-0.42	-0.29
Other Non Operating Income (Expenses)	1.6	2.22	-0.24	2.8	-2.31
EBT Excluding Unusual Items	0.38	0.92	-4.03	-3.89	-10.09
Other Unusual Items	-0.29	-	-	-	-
Pretax Income	0.09	0.92	-4.03	-3.89	-10.09
Income Tax Expense	0.43	1.18	0.21	0	-
Earnings From Continuing Operations	-0.34	-0.26	-4.25	-3.89	-10.09
Minority Interest in Earnings	-0.78	-1.57	-0.45	0.13	0.04
Net Income	-1.12	-1.83	-4.7	-3.76	-10.05
Net Income to Common	-1.12	-1.83	-4.7	-3.76	-10.05
Shares Outstanding (Basic)	4	4	4	4	3
Shares Outstanding (Diluted)	4	4	4	4	3
Shares Change (YoY)	3.92%	8.96%	3.23%	10.87%	38.59%
EPS (Basic)	-0.25	-0.43	-1.19	-0.98	-2.91
EPS (Diluted)	-0.25	-0.43	-1.19	-0.98	-2.91
Free Cash Flow	0.48	-1.59	-3.95	-6.09	-6.67
Free Cash Flow Per Share	0.11	-0.37	-1.00	-1.59	-1.93
Gross Margin	89.93%	88.96%	87.71%	82.34%	61.73%
Operating Margin	-4.72%	-4.24%	-27.85%	-244.86%	-3816.33%
Profit Margin	-4.22%	-6.23%	-34.41%	-147.09%	-5126.02%
Free Cash Flow Margin	1.80%	-5.42%	-28.92%	-238.10%	-3403.06%
EBITDA	-1.21	-1.21	-3.77	-6.23	-7.44
EBITDA Margin	-4.56%	-4.12%	-27.61%	-243.49%	-
D&A For EBITDA	0.04	0.04	0.03	0.04	0.04
EBIT	-1.26	-1.25	-3.8	-6.27	-7.48
EBIT Margin	-4.72%	-4.24%	-27.85%	-244.86%	-
Effective Tax Rate	501.18%	128.51%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.